Article Contents ::
- 1 The Brand Name MITONCO Has Generic Salt :: Mitomycin
- 2 MITONCO Is From Company Vhb Priced :: Rs. 643
- 3 MITONCO have Mitomycin is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
- 4 Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name MITONCO Has Generic Salt :: Mitomycin
MITONCO Is From Company Vhb Priced :: Rs. 643
MITONCO have Mitomycin is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Mitomycin | INJ | Rs. 643 | V. |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / V. |
| MITONCO | Vhb | 10MG | V. | Rs. 643 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Vhb :: MITONCO | Mitomycin | Anti Neoplastic Agents | Anti Neoplastic Agents |
Indications for Drugs ::
Solid tumours, bladder tumours, stomach cancer, pancreas cancer
Drug Dose ::
Adult: IV: Solid tumours Suggested regimen: Initial: 10-20 mg/m2; may repeat 6-8 wkly depending on blood count. Do not repeat if leucocyte and platelet counts are below acceptable levels. Do not re-administer if the nadir of the leucocyte count is <2,000 cells/mm3. Intravesical Superficial bladder tumours Instill 10-40 mg 1-3 times/wk for a total of 20 doses. Prevention of recurrent bladder tumours Instill 20 mg 2 wkly or 40 mg 1-3-mthly. Renal Impairment Serum creatinine >1.7 mg/dL: Avoid use CrCl <10 mL/min: Decrease dose by 25% CAPD: Decrease dose by 25% Contraindication ::
Thrombocytopenia, coagulation disorders, increase in bleeding tendency due to other causes. Renal impairment, potentially severe infections. Pregnancy and lactation.
Drug Precautions ::
Repeated haematologic studies are necessary during treatment and for at least 7 wk after discontinuation of the drug. Discontinue use when the leucocyte count decreases to <4000/mm3 or the platelet count decreases to <150,000/mm3 or if a progressive decline in either occurs. Monitor patient for signs of renal or pulmonary toxicity. Drug Side Effects ::
CHF; fever; alopecia, nail banding/discolouration; nausea, vomiting, anorexia; anaemia; rash; stomatitis; paraesthesia; increased creatinine; interstitial pneumonitis, infiltrates, dyspnoea, cough; malaise, pruritus, extravasation, bladder fibrosis/contraction (intravesical admin). Potentially Fatal: Myelosuppression, haemolytic-uraemic syndrome.
Pregnancy category ::
4
Drug Mode of Action ::
Mitomycin is an antineoplastic antibiotic which is enzymatically reduced to its active metabolite w/in susceptible cells. The active metabolite appears to cause cross-linking of DNA (primarily w/ guanine and cytosine pairs). It is also active against gm+ve bacteria and some viruses.
Drug Interactions ::
Increased incidence of cardiotoxicity w/ doxorubicin. Potentially Fatal: Increased risk of intravascular haemolysis and renal failure w/ fluorouracil. Increased risk of haemolytic uraemic syndrome w/ tamoxifen. Acute pulmonary toxicity w/ vinca alkaloids (e.g. vinblastine, vinorelbine). Increased bone marrow depressant effects of aclarubicin.
